Organisation paid for research Program year 2025 Source: CMS Open Payments

Visionaire Products Inc

Neither a doctor nor a teaching hospital

Research payments

$336,460

96 payments

Through program year 2025, Visionaire Products Inc is reported as receiving $336,460 in research payments, across 96 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$103,295	56
2024	Research	$94,105	17
2023	Research	$132,398	20
2022	Research	$6,663	3

Breakdown

Who paid Research payments · program years 2022–2025

Roche TCRC, Inc. $255,423 50 payments
Regeneron Pharmaceuticals, Inc. $81,037 46 payments

Studies the money was for Research payments · program years 2022–2025

Phase 2 Study to Investigate Ro7200220 in Diabetic MacUlar Edema $255,423 50 payments
A Phase 3b Single-Arm Study of Aflibercept 8 mg in Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) $68,438 25 payments
A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration $12,599 21 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.